Rezolute (RZLT) CMO reports purchase of 28,000 common shares

Rhea-AI Filing Summary

Rezolute, Inc.'s Chief Medical Officer reported buying additional company stock. On 12/16/2025, the officer purchased 28,000 common shares of Rezolute at a price of $1.7 per share. After this transaction, the officer beneficially owned 308,352 common shares directly and 15,500 common shares indirectly through an IRA. This filing highlights increased personal exposure of a senior executive to Rezolute’s equity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBERTS BRIAN KENNETH

(Last) (First) (Middle)

C/O REZOLUTE, INC.

275 SHORELINE DRIVE, SUITE 500

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rezolute, Inc. [ RZLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/16/2025		P		28,000	A	$1.7	308,352	D
Common Shares								15,500	I	Held in IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Brian Kenneth Roberts	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rezolute (RZLT) disclose in this filing?

The filing shows Rezolute’s Chief Medical Officer bought 28,000 common shares of Rezolute, Inc. on 12/16/2025 at $1.7 per share.

Who is the insider involved in this Rezolute (RZLT) transaction and what is their role?

The reporting person is an officer of Rezolute, Inc., serving as the company’s Chief Medical Officer.

How many Rezolute (RZLT) shares does the officer own after the reported transaction?

Following the transaction, the officer beneficially owned 308,352 common shares directly and 15,500 common shares indirectly held in an IRA.

What was the purchase price for the Rezolute (RZLT) shares bought by the officer?

The Chief Medical Officer bought 28,000 common shares of Rezolute, Inc. at a price of $1.7 per share.

Does this Rezolute (RZLT) insider filing report any derivative securities?

The provided Table II header refers to derivative securities, but no specific derivative transactions or positions are listed in the excerpt.

Is this Rezolute (RZLT) insider report filed by one or multiple reporting persons?

The document indicates the form is filed by one reporting person, not by a group.